Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments

Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is still no way to slow disease progression and no known cures. NanoTemper is committed to providing new solutions for studying these diseases and developing new treatments. This webinar will show how aggregation of intrinsically disordered proteins is a common characteristic of all neurodegenerative disorders and also how NanoTemper’s instruments can overcome the challenges of other technologies when studying them.

Previous Article
Cyrill Brunner gets Explorer Award for innovative approach to advance drug discovery research using computer modeling
Cyrill Brunner gets Explorer Award for innovative approach to advance drug discovery research using computer modeling

Meet Cyrill Brunner, Senior PhD candidate at ETH in Zurich, Switzerland (preparing to defend his thesis as ...

Up next
Humanized Selective CD19CAR-T Cells Treatment Shows Efficacy in B-ALL Patients Who Relapsed after Receiving Murine-Based CD19CAR-T Therapies
Humanized Selective CD19CAR-T Cells Treatment Shows Efficacy in B-ALL Patients Who Relapsed after Receiving Murine-Based CD19CAR-T Therapies

Ready to characterize your most challenging interactions?

Discover tools to measure binding affinity

Learn more